RCM Technologies, Inc. (RCMT) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the thirteen-week period ended April 4, 2026 (Fiscal Q1 2026). RCM Technologies, Inc. provides business and technology solutions through three primary segments: Specialty Healthcare, Engineering, and Life Sciences, Data and Solutions. The company operates globally with a significant presence in the United States, Canada, Puerto Rico, and Europe.
Key Financial Metrics
| Metric | Q1 2026 (13 Weeks) | Q1 2025 (13 Weeks) |
|---|---|---|
| Revenue | $83.0 million | $84.5 million |
| Gross Profit | $22.0 million (26.5% margin) | $22.0 million (26.0% margin) |
| Operating Income | $5.9 million (7.2% margin) | $6.6 million (7.8% margin) |
| Net Income | $3.8 million | $4.2 million |
| Diluted EPS | $0.52 | $0.54 |
| Cash from Operations | $2.7 million | $16.7 million |
| Revolving Credit Borrowings | $28.8 million | $24.7 million (Prior Year End) |
| Cash and Equivalents | $2.6 million | $2.9 million (Prior Year End) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $1.4 million (1.7%) year-over-year. This was driven by a significant $6.0 million (18.7%) drop in the Engineering segment, partially offset by a $4.8 million (11.1%) increase in Specialty Healthcare.
- Segment Performance:
- Specialty Healthcare: Revenue grew due to increased demand from school clients, though non-school revenue declined due to a lost corrections facility contract. Gross margin decreased slightly to 27.9%.
- Engineering: Revenue fell due to gaps in Energy Services EPC projects and reduced spending in Aerospace. Despite lower revenue, gross margin improved to 20.3% due to a favorable mix shift.
- Life Sciences: Revenue remained relatively flat (-2.8%) with a slight decline in gross margin to 37.3%.
- Cash Flow Volatility: Operating cash flow dropped significantly to $2.7 million from $16.7 million in the prior year. This was primarily due to a $3.9 million increase in accounts receivable (cash usage) compared to a $9.6 million decrease (cash generation) in the prior year, attributed to timing of milestones on fixed-price contracts.
- Share Repurchases: The company repurchased 348,366 shares for $6.7 million during the quarter. Approximately $28.3 million remains available under the current repurchase program.
Guidance, Outlook, and Risks
- Outlook: Management notes the market is cyclical and sensitive to economic conditions. They anticipate continued demand for outsourcing in AI, Quality by Design (QbD), and process automation. The company expects to maintain compliance with financial covenants.
- Debt Facility: The revolving credit facility was amended in February 2026 to increase the commitment limit to $75.0 million (temporarily through August 2026) from $65.0 million. Borrowings increased to $28.8 million during the quarter.
- Material Weaknesses in Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of April 4, 2026, due to material weaknesses. These include deficiencies in entity-level controls, management review documentation, risk assessment, and timekeeping system change management. Remediation efforts are underway but the timing of full remediation is uncertain.
- Risks: Key risks include customer concentration (two customers represented 40.4% of revenue), reliance on the healthcare industry, credit/collection risks, and potential impacts from litigation or regulatory changes.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of remediation plans for the disclosed material weaknesses in internal controls over financial reporting.
- Engineering Segment Recovery: Monitor the Engineering segment for signs of recovery in Energy Services and Aerospace revenue, which drove the overall revenue decline.
- Accounts Receivable Aging: Review the aging of accounts receivable given the significant cash flow drag from increased receivables in the Engineering segment.
- Customer Concentration: Assess the stability of the two largest customers in the Specialty Healthcare segment, which collectively accounted for over 40% of total revenue.
- Debt Utilization: Track the utilization of the revolving credit facility, noting the temporary increase in capacity and the current draw of $28.8 million.